AU607584B2 - A pharmaceutical composition for relieving side effects of platinum-containing drugs - Google Patents

A pharmaceutical composition for relieving side effects of platinum-containing drugs Download PDF

Info

Publication number
AU607584B2
AU607584B2 AU29553/89A AU2955389A AU607584B2 AU 607584 B2 AU607584 B2 AU 607584B2 AU 29553/89 A AU29553/89 A AU 29553/89A AU 2955389 A AU2955389 A AU 2955389A AU 607584 B2 AU607584 B2 AU 607584B2
Authority
AU
Australia
Prior art keywords
ulinastatin
cisplatinum
administration
platinum
side effects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU29553/89A
Other languages
English (en)
Other versions
AU2955389A (en
Inventor
Yoshinosuke Fukuchi
Toshio Sato
Kenji Toba
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mochida Pharmaceutical Co Ltd
Original Assignee
Mochida Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharmaceutical Co Ltd filed Critical Mochida Pharmaceutical Co Ltd
Publication of AU2955389A publication Critical patent/AU2955389A/en
Application granted granted Critical
Publication of AU607584B2 publication Critical patent/AU607584B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU29553/89A 1988-02-08 1989-02-02 A pharmaceutical composition for relieving side effects of platinum-containing drugs Ceased AU607584B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP63-26918 1988-02-08
JP63026918A JPH01203334A (ja) 1988-02-08 1988-02-08 白金を含有する薬剤の副作用軽減剤

Publications (2)

Publication Number Publication Date
AU2955389A AU2955389A (en) 1989-08-10
AU607584B2 true AU607584B2 (en) 1991-03-07

Family

ID=12206574

Family Applications (1)

Application Number Title Priority Date Filing Date
AU29553/89A Ceased AU607584B2 (en) 1988-02-08 1989-02-02 A pharmaceutical composition for relieving side effects of platinum-containing drugs

Country Status (8)

Country Link
US (1) US4950465A (zh)
EP (1) EP0327999B1 (zh)
JP (1) JPH01203334A (zh)
AT (1) ATE76754T1 (zh)
AU (1) AU607584B2 (zh)
CA (1) CA1329541C (zh)
DE (1) DE68901656T2 (zh)
GR (1) GR3005276T3 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466678A (en) * 1992-09-04 1995-11-14 Fuji Kagaku Kogyo Kabushiki Kaisha Co-administration of S-adenosyl-L-methionine to reduce the nephrotoxicity of cisplatin therapy
CN1160123C (zh) * 2003-05-26 2004-08-04 广东天普生化医药股份有限公司 乌司他丁用于治疗严重急性呼吸综合征的用途及其药物组合物
MX2019014354A (es) * 2017-05-30 2020-07-28 Zavante Therapeutics Inc Metodos para identificar nuevos regimenes de dosificacion.
BR112022017718A2 (pt) 2020-03-05 2022-11-16 Diamedica Usa Inc Polipeptídeos de ulinastatina
WO2024111404A1 (ja) * 2022-11-21 2024-05-30 協和発酵バイオ株式会社 抗がん剤により誘発される急性腎障害の予防又は治療剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6028928A (ja) * 1983-07-27 1985-02-14 Meiji Seika Kaisha Ltd 制癌剤の副作用軽減剤
IT1200467B (it) * 1985-05-06 1989-01-18 Boehringer Biochemia Srl Formulazione farmaceutica
JPS62106021A (ja) * 1985-11-01 1987-05-16 Eisai Co Ltd エラスタ−ゼの利用方法

Also Published As

Publication number Publication date
GR3005276T3 (zh) 1993-05-24
AU2955389A (en) 1989-08-10
JPH0560813B2 (zh) 1993-09-03
ATE76754T1 (de) 1992-06-15
EP0327999A1 (en) 1989-08-16
DE68901656D1 (de) 1992-07-09
DE68901656T2 (de) 1993-02-11
JPH01203334A (ja) 1989-08-16
EP0327999B1 (en) 1992-06-03
US4950465A (en) 1990-08-21
CA1329541C (en) 1994-05-17

Similar Documents

Publication Publication Date Title
Bonkowsky et al. Repression of the overproduction of porphyrin precursors in acute intermittent porphyria by intravenous infusions of hematin
US4485095A (en) Pronase used for the treatment of diseases of the liver and kidneys in humans and animals
US4745099A (en) Pharmaceutical composition for the treatment of the anemia of malignant tumors
US4137307A (en) Process for preparing haptoglobin aqueous solution using strong anion exchanger
US4748157A (en) Composition for gastrointestinal ulcers
AU607584B2 (en) A pharmaceutical composition for relieving side effects of platinum-containing drugs
US4061735A (en) Haptoglobin in aqueous solution and process for preparing the same
EP0124018B1 (en) Pharmaceutical preparation containing purified fibronectin
Ter Borg et al. Use of sodium hydroxide solution to clear partially occluded vascular access ports
JPS6237615B2 (zh)
Tihen Central pontine myelinolysis and Rosenthal fibers of the brainstem: association with emaciation and prolonged intravenous hyperalimentation
EP0278416B1 (en) Use of human blood coagulation factor xiii for the treatment of ulcerative colitis
Hiraoka et al. Systemic Capillary Leak Syndrome Associated with Multiple Myeloma of IgG κType
Sinclair et al. Intravenous Iron in Hypochromic Anaemia Associated with Rheumatoid Arthritis
US4479937A (en) Process of treating inflammation with human urinary thiol protease inhibitor
AU725441B2 (en) An agent for preventing and/or treating multiple organ failure
Umeki et al. Urinastatin (Kunitz-type proteinase inhibitor) reducing cisplatin nephrotoxicity
Hassan Treatment of meprobamate overdose with repeated oral doses of activated charcoal
Kirschke et al. Coagulation and fibrinolysis in children with acute lymphoblastic leukaemia treated according to the COALL-05-92-protocol
Jaffe et al. Inhibition of gastrin activity by incubation with antibodies to the C-terminal tetrapeptide of gastrin
Thomson et al. Acute myelogenous leukemia treated with daunomycin associated with nephrotic syndrome
Keipert et al. Metabolism, Distribution, and Excretion of HbXL: A Nondissociating Interdimerically Crosslinked Hemoglobin with Exceptional Oxygen Offloading Capability
Kopple et al. Effects of amino acid infusion and renal failure on the uptake and release of amino acids by the dog kidney
Folb Intravenous infusions
Fukuoka et al. A phase I study of chronic daily dosing of oral etoposide in combination with cisplatin for patients with advanced cancer